Mar 23, 2021 | News, Press, Uncategorized
Round was co-led by Casdin Capital and Redmile Group Fidelity Management & Research Company LLC, D1 Capital Partners, and Perceptive Advisors are among the new investors VANCOUVER, Wash., March 23, 2021 /PRNewswire/ — AbSci, a pioneering synthetic biology company...
Feb 22, 2021 | Uncategorized
VANCOUVER, Wash., – February 22, 2021 – AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential...
Feb 3, 2021 | Uncategorized
-Second molecule addressed under the collaboration agreement, first to exploit AbSci discovery technologies- VANCOUVER, Wash., February 3, 2021 /PRNewswire/ — AbSci, a pioneering synthetic biology company enabling drug discovery and biomanufacturing of...
Jan 12, 2021 | Uncategorized
Integration of Denovium Engine™ with AbSci’s Protein Printing™ Platform to enable creation of novel biotherapeutics and manufacturing cell lines with the click of a button Vancouver, Wash., January 12, 2021 – AbSci, a leading synthetic biology company enabling drug...
Jan 7, 2021 | Uncategorized
VANCOUVER, Wash., Jan. 7, 2021 /PRNewswire/ — AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next generation biotherapeutics, today announced that Sean McClain, Founder and CEO, will present virtually at the 39th...
